Roger Echols

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti, Roger Echols, Yuko Matsunaga et al. · The Lancet Infectious Diseases · 2020 · 732 citations

Antimicrobial Susceptibility, Health Sciences, Carbapenem-resistant Gram-negative Bacteria +11

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink, Yuko Matsunaga, Mari Ariyasu et al. · The Lancet Infectious Diseases · 2020 · 432 citations

Antibiotics, Respiratory Infection, Sepsis +4

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Simon Portsmouth, David van Veenhuyzen, Roger Echols et al. · The Lancet Infectious Diseases · 2018 · 387 citations

Urological Research, Urology, Gram-negative Uropathogens +10

Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy

Deepak Kapoor, Ira Klimberg, G.H. Malek et al. · Urology · 1998 · 251 citations

Urology, Medicine, Transrectal Prostate Biopsy +5

<i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016

Meredith Hackel, Masakatsu Tsuji, Yoshinori Yamano et al. · Antimicrobial Agents and Chemotherapy · 2017 · 225 citations · Full text